Ossdsign AB (Publ) reported revenues for the period October - November 2023. For the period, company reported Preliminary total revenues amount to SEK 25.2 million, mainly attributable to a continued strong market performance of the orthobiologics franchise and some extraordinary orders from a large hospital system. According to preliminary and unaudited data, sales of OssDsign Catalyst amounted to SEK 18.8 million during the period of October - November 2023, whereas OssDsign Cranial recorded sales of SEK 6.4 million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
9.34 SEK | -1.68% | +1.63% | +16.75% |
Jun. 25 | OssDsign AB Approves Election of Christer Fåhraeus as Ordinary Board Member | CI |
May. 14 | Transcript : OssDsign AB, Q1 2024 Earnings Call, May 14, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.75% | 87.99M | |
+11.75% | 127B | |
+1.53% | 12.35B | |
-18.47% | 7.1B | |
+56.20% | 6.78B | |
+9.27% | 3.47B | |
-15.41% | 2.6B | |
-18.25% | 1.91B | |
-27.00% | 1.62B | |
-37.52% | 1.45B |
- Stock Market
- Equities
- OSSD Stock
- News OssDsign AB
- Ossdsign AB Reports Revenues for the Period October - November 2023